𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Expression of receptor activator of nuclear factor -κB ligand, receptor activator of nuclear factor -κB, and osteoprotegerin, following low-level laser treatment on deproteinized bovine bone graft in rats

✍ Scribed by Yong-Deok Kim; Won-Wook Song; Seong-Sik Kim; Gyu-Cheon Kim; Dae-Seok Hwang; Sang-Hun Shin; Uk-Kyu Kim; Jong-Ryoul Kim; In-Kyo Chung

Publisher
Springer-Verlag
Year
2008
Tongue
English
Weight
574 KB
Volume
24
Category
Article
ISSN
0268-8921

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of disease-modifying antirheumat
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand
✍ Chang-Keun Lee; Eun Young Lee; Son Mi Chung; Se Hwan Mun; Bin Yoo; Hee-Bom Moon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract ## Objective To demonstrate the effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through their effects on receptor activator of nuclear factor κB (RANK), osteoprotegerin (OPG), and RANK ligand (RANKL). ## Methods Peripheral b

Plasma levels of receptor activator of n
Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma
✍ Donatella Granchi; Alberto Garaventa; Ilaria Amato; Paolo Paolucci; Nicola Baldi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB

## Abstract Earlier reports showed that the balance between receptor activator of nuclear factor‐κB ligand (RANKL) and its decoy‐receptor osteoprotegerin (OPG) plays an important role in the pathogenesis of metastatic osteolysis induced by neuroblastoma cells. In this study, we investigated whether

Receptor activator of nuclear factor-κB
Receptor activator of nuclear factor-κB ligand and osteoprotegerin : Potential implications for the pathogenesis and treatment of malignant bone diseases
✍ Lorenz C. Hofbauer; Andreas Neubauer; Armin E. Heufelder 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 1 views

## Background: The current review summarizes the roles of the ligand, receptor activator of nuclear factor-kappab ligand (rankl), its receptor, receptor activator of nuclear factor-kappab (rank), and its decoy receptor, osteoprotegerin (opg), on osteoclast biology and bone resorption. furthermore,